Advanced glycation end products affect growth and function of osteoblasts

Clinical and Experimental Rheumatology

Volumn 29, Issue 4, 2011, Pages 650-660

  Franke, Sybille ^a   Rüster, Christiane ^a   Pester, Julia ^a   Hofmann, Gunther ^a   Oelzner, Peter ^a   Wolf, Gunter ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Advanced glycation end products; Bone formation and resorption; NF B; Osteoblasts; RAGE (receptor for advanced glycation end products)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERSTITIAL COLLAGENASE; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ADVANCED GLYCATION END PRODUCTS BOVINE SERUM ALBUMIN; ADVANCED GLYCATION END PRODUCTS-BOVINE SERUM ALBUMIN; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BOVINE SERUM ALBUMIN; IMMUNOGLOBULIN RECEPTOR; RELA PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; ALKALINE PHOSPHATASE GENE; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE MATRIX; BONE METABOLISM; CELL CYCLE; CELL CYCLE ARREST; CELL DEATH; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL STIMULATION; COLLAGEN TYPE 1 GENE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LUCIFERASE ASSAY; MALE; MATRIX METALLOPROTEINASE 1 GENE; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCALCIN GENE; OSTEOCLAST DIFFERENTIATION FACTOR GENE; OSTEOCLASTOGENESIS; OSTEOPROTEGERIN GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS GENE; TUMOR NECROSIS FACTOR ALPHA GENE; UPREGULATION; WESTERN BLOTTING; AGED; CELL CULTURE; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MIDDLE AGED; NECROSIS; OSTEOCLAST; PATHOLOGY; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

AGED; ALKALINE PHOSPHATASE; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN TYPE I; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENES, REPORTER; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; NECROSIS; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERUM ALBUMIN, BOVINE; TIME FACTORS; TRANSCRIPTION FACTOR RELA; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80055083729     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. SIPOS W, PIETSCHMANN P, RAUNER M, KERSCHAN-SCHINDL K, PATSCH J: Pathophysiology of osteoporosis. Wien Med Wochenschr 2009; 159: 230-4.
2. FINI M, CARPI A, BORSARI V et al.: Bone remodeling, humoral networks and smart biomaterial technology for osteoporosis. Front Biosci (Schol Ed) 2010; 2: 468-82.
3. ULRICH P, CERAMI A: Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21.
4. SCHMIDT AM, YAN SD, YAN SF, STERN DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-55.
5. BIERHAUS A, HUMPERT PM, MORCOS M et al.: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83: 876-86.
6. TAKAGI M, KASAYAMA S, YAMAMOTO T et al.: Advanced glycation endproducts stimulate interleukin-6 production by human bonederived cells. J Bone Miner Res 1997; 12: 439-46.
7. ZHOU Z, IMMEL D, XI CX et al.: Regulation of osteoclast function and bone mass by RAGE. J Exp Med 2006; 203: 1067-80.
8. CHAROONPATRAPONG K, SHAH R, ROBLING AG et al.: HMGB1 expression and release by bone cells. J Cell Physiol 2006; 207: 480-90.
9. SANGUINETI R, STORACE D, MONACELLI F, FEDERICI A, ODETTI P: Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci 2008; 1126: 166-72.
10. RAGGATT LJ, PARTRIDGE NC: Cellular and molecular mechanisms of bone remodelling. J Biol Chem 2010.
11. KATAYAMA Y, AKATSU T, YAMAMOTO M, KUGAI N, NAGATA N: Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 1996; 11: 931-7.
12. MCCARTHY AD, ETCHEVERRY SB, BRUZZONE L, CORTIZO AM: Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells. Mol Cell Biochem 1997; 170: 43-51.
13. MCCARTHY AD, ETCHEVERRY SB, BRUZZONE L, LETTIERI G, BARRIO DA, CORTIZO AM: Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol 2001; 2: 16.
14. MCCARTHY AD, ETCHEVERRY SB, CORTIZO AM: Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetol 2001; 38: 113-22.
15. CORTIZO AM, LETTIERI MG, BARRIO DA, MERCER N, ETCHEVERRY SB, MCCARTHY AD: Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signalregulated kinases (ERK). Mol Cell Biochem 2003; 250: 1-10.
16. MCCARTHY AD, UEMURA T, ETCHEVERRY SB, CORTIZO AM: Advanced glycation endproducts interefere with integrin-mediated osteoblastic attachment to a type-I collagen matrix. Int J Biochem Cell Biol 2004; 36: 840-8.
17. MERCER N, AHMED H, MCCARTHY AD, ETCHEVERRY SB, VASTA GR, CORTIZO AM: AGE-R3/galectin-3 expression in osteoblast- like cells: regulation by AGEs. Mol Cell Biochem 2004; 266: 17-24.
18. MERCER N, AHMED H, ETCHEVERRY SB, VASTA GR, CORTIZO AM: Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells. Mol Cell Biochem 2007; 306: 87-94.
19. GANGOITI MV, CORTIZO AM, ARNOL V, FELICE JI, MCCARTHY AD: Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. Eur J Pharmacol 2008; 600: 140-7.
20. SCHURMAN L, MCCARTHY AD, SEDLINSKY C et al.: Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008; 116: 333-40.
21. OGAWA N, YAMAGUCHI T, YANO S, YAMAUCHI M, YAMAMOTO M, SUGIMOTO T: The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 2007; 39: 871-5.
22. YAMAMOTO T, OZONO K, MIYAUCHI A et al.: Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 2001; 38(4 Suppl. 1): S161-4.
23. YAMAMOTO T, OZONO K: [Role of advanced glycation endproducts in adynamic bone disease]. Clin Calcium 2001; 11: 1044-7.
24. ALIKHANI M, ALIKHANI Z, BOYD C et al.: Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase andcytosolic apoptotic pathways. Bone 2007; 40: 345-53.
25. FRANKE S, SIGGELKOW H, WOLF G, HEIN G: Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 2007; 113: 154-61.
26. RABBANI N, THORNALLEY PJ: Glycation research in amino acids: a place to call home. Amino Acids 2010 Oct 28 [Epub ahead of print].
27. FRANKE S, SOMMER M, RUSTER C et al.: Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. Arthritis Res Ther 2009; 11: R136.
28. FRANKE S, MULLER A, SOMMER M, BUSCH M, KIENTSCH-ENGEL R, STEIN G: Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation endproducts (AGEs) in patients after renal transplantation. Clin Nephrol 2003; 59: 88-97.
29. PFAFFL MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
30. PANAGAKOS FS, KUMAR S: Differentiation of human osteoblastic cells in culture: modulation of proteases by extracellular matrix and tumor necrosis factor-alpha. Inflammation 1995; 19: 423-43.
31. HOFBAUER LC, HEUFELDER AE: Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243-53.
32. MATSUMOTO S, YOSHIDA T, MURATA H et al.: Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGERAGE interaction. Biochemistry 2008; 47: 12299-311.
33. SEVILLANO N, GIRON MD, SALIDO M, VARGAS AM, VILCHES J, SALTO R: Internalization of the receptor for advanced glycation end products (RAGE) is required to mediate intracellular responses. J Biochem 2009; 145: 21-30.
34. RUSTER C, BONDEVA T, FRANKE S, FORSTER M, WOLF G: Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrol Dial Transplant 2008; 23: 2179-91.
35. CHANG JK, LI CJ, LIAO HJ, WANG CK, WANG GJ, HO ML: Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts. Toxicology 2009; 258: 148-56.
36. BU S, YAMANAKA M, PEI H et al.: Dihydrosphingosine 1-phosphate stimulates MMP1 gene expression via activation of ERK1/2- Ets1 pathway in human fibroblasts. FASEB J 2006; 20: 184-6.
37. WADA T, NAKASHIMA T, HIROSHI N, PENNINGER JM: RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12: 17-25.
38. LI J, SCHMIDT AM: Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997; 272: 16498-506.
39. TANAKA N, YONEKURA H, YAMAGISHI S, FUJIMORI H, YAMAMOTO Y, YAMAMOTO H: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factoralpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 275: 25781-90.
40. GILBERT L, HE X, FARMER P et al.: Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141: 3956-64.
41. DING J, GHALI O, LENCEL P et al.: TNF-alpha and IL-1beta inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci 2009; 84: 499-504.